Our law firm is investigating Evolus, Inc. (NASDAQ: EOLS) after a U.S. trade-agency Judge reportedly found the company in violation of the Tariff Act of 1930 and recommended barring imports of Evolus’s Jeuveau wrinkle treatment product for 10 years.

On this news, Evolus stock dropped roughly 30% in one day, significantly harming investors.

Lost Money in EOLS?

You may have a claim. Get a free and confidential consultation.

  • This field is for validation purposes and should be left unchanged.

1-866-511-6647

Evolus Stock Plummets 30%: Judge Reportedly Finds Jeuveau is Made with Stolen Trade Secrets

On July 6, 2020, Evolus issued a press release stating that the Judge overseeing the U.S. International Trade Commission case filed by Allergan and Medytox against Evolus and Daewoong released a Notice of Initial Determination. The Judge reportedly found a violation of the Tariff Act of 1930 with the company’s Jeuveau wrinkle treatment, according to the release.

TheStreet reports that the Judge further recommended barring imports of Jeuveau for 10 years. According to the news source,

The judge found that Jeuveau, produced by Newport Beach, Calif., medical-beauty company Evolus and South Korean health-care group Daewoong, is made with trade secrets stolen from Allergan and Medytox.

The Judge’s ruling is reportedly an initial decision, and is subject to final determination of the International Trade Commission (ITC). According to TheStreet, the Commission is scheduled to complete its investigation in November of this year.

Following this news, Evolus’s share price dropped nearly 30%. If you lost money in Evolus, you may have a claim.

Our Securities Lawyers Have a Winning Record Against Companies Like Evolus

Our securities lawyers have recovered over a billion dollars on behalf of our clients against behemoths, such as Chase Bank, Mastercard, and Anthem Blue Cross Blue Shield. Read more about our results.

You “shouldn’t presume that powerful banks and other powerful interests can just get away with doing bad things. Good, qualified counsel that are committed to a cause can usually figure out how to prosecute such cases effectively and prevail.”

Eric Gibbs, award-winning securities attorney

Praise from the Courts

Federal judge in our AT&T class action:

“I’ve always found them to be extraordinary counsel in terms of their preparation and their professionalism.”

Federal judge in our Chase lawsuit (resulting in $100 million settlement):

They “fought tooth and nail, down to the wire” to achieve “the best settlement that they could under the circumstances.”

Read more about what judges say about us.

Gibbs Law Group's Financial Fraud Experience

Gibbs Law Group’s financial fraud and securities lawyers have more than two decades of experience prosecuting fraud. Our attorneys have successfully litigated against some of the largest companies in the United States, and we have recovered more than a billion dollars on our clients’ behalf.

We have fought some of the most complex cases brought under federal and state laws nationwide, and our attorneys have been recognized with numerous awards and honors for their accomplishments, including Top 100 Super Lawyers in Northern California, Top Plaintiff Lawyers in California, The Best Lawyers in America, and rated AV Preeminent (among the highest class of attorneys for professional ethics and legal skills).

Michael Schrag

Michael has over 20 years of experience representing individual and small business plaintiffs against the world’s large financial institutions, including Visa, Mastercard, and Chase.

Eileen Epstein

Eileen works closely with investors in securities cases and has over a decade of experience in the legal world. She received her law degree from American University in 2005.

David Stein

David’s advocacy has generated major recoveries for consumers impacted by financial fraud. He was named to the Top 40 Under 40 by Daily Journal and a “Rising Star in Class Actions” by Law360.

Amanda Karl

Amanda is spearheading a securities lawsuit against NantHealth concerning fraudulent statements to investors about the success of its key product.